Overview

Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2029-03-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of adjuvant therapy with liposomal irinotecan in combination with oxaliplatin, and S-1 compared with capecitabine combined with capecitabine in participants with pancreatic ductal adenocarcinoma after radical surgery.

Phase:

PHASE3

Details

Lead Sponsor:

CSPC Ouyi Pharmaceutical Co., Ltd.

Treatments:

Capecitabine
Gemcitabine
irinotecan sucrosofate
Oxaliplatin
S 1 (combination)